STOCKHOLM, SWEDEN--(Marketwire - June 21, 2010) - Biovitrum AB (publ) will be listed under
its new company name, Swedish Orphan Biovitrum AB (publ) with effect from
June 24, 2010.
+-----------------------+------------+
|New short name: |SOBI |
+-----------------------+------------+
|Unchanged ISIN code: |SE0000872095|
+-----------------------+------------+
|Unchanged Round lot: |1 |
+-----------------------+------------+
|Unchanged orderbook ID:|36316 |
+-----------------------+------------+
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical
company with an international market presence. The company is focused on
providing and developing specialist pharmaceuticals for rare disease
patients
with high medical needs. The portfolio consists of about 60 marketed
products
and an emerging late stage clinical development pipe-line. Our focus areas
are:
hemophilia, autoimmune diseases, metabolic diseases and cancer supportive
care.
Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and
approximately 500 employees. The head office is located in Sweden and the
share
(STO:BVT ) is listed on NASDAQ OMX Stockholm. For more information please
visitwww.sobi.com.
Swedish Orphan Biovitrum may be required to disclose the information
provided
herein pursuant to the Swedish Securities Markets Act. The information was
provided for public release on June 21, 2010 at 4 p.m. CET.
[HUG#1425813]
Press release June 21 in pdf format:
http://hugin.info/134557/R/1425813/373884.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients. The owner of this announcement warrants that: (i) the
releases contained herein are protected by copyright and other applicable
laws; and (ii) they are solely responsible for the content, accuracy and
originality of the information contained therein. All reproduction for
further distribution is prohibited.
